17-Hydroxy-jolkinolide A inhibits osteoclast differentiation through suppressing the activation of NF-κB and MAPKs

被引：21

作者：

Wang, Yingjian ^{[1
,2
]}

Xu, Xiaohan ^{[1
]}

Wang, Hong-bing ^{[3
]}

Wu, Donglin ^{[4
]}

Li, Xiao-ou ^{[5
]}

Peng, Qisheng ^{[1
]}

Liu, Ning ^{[6
]}

Sun, Wan-chun ^{[1
]}

机构：

[1] Jilin Univ, Inst Zoonosis, Minist Educ, Key Lab Zoonosis, Changchun 130062, Peoples R China

[2] Jilin Univ, China Japan Union Hosp, Dept Obstet & Gynaecol, Changchun 130033, Peoples R China

[3] Tongji Univ, Sch Life Sci & Technol, Shanghai 200092, Peoples R China

[4] Jilin Prov Ctr Dis Control & Prevent, Changchun 130062, Peoples R China

[5] Tumor Hosp Jilin Prov, Clin Lab, Changchun 130022, Peoples R China

[6] Jilin Univ, Clin Hosp 2, Cent Lab, Changchun 130041, Peoples R China

来源：

INTERNATIONAL IMMUNOPHARMACOLOGY | 2015年 / 29卷 / 02期

基金：

中国国家自然科学基金;

关键词：

Osteoclast; Bone resorption; RANKL; NF-kappa B; MAPK; 17-Hydroxy-jolkinolide A; EUPHORBIA-FISCHERIANA; MURINE MACROPHAGES; SIGNALING PATHWAYS; BONE-RESORPTION; PROTEIN-KINASE; EXPRESSION; NFATC1; OSTEOPOROSIS; SURVIVAL;

D O I：

10.1016/j.intimp.2015.10.004

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Osteoclasts (OC) are bone-specific multinucleated giant cells (MNCs) derived from the monocyte/macrophage hematopoietic lineage cells. Inhibiting osteoclast formation is considered as an effective therapeutic approach for the treatment of the pathological bone loss. In this study, we investigated effects of 17-hydroxy-jolkinolide A (HJA), an ent-abietane diterpenoid isolated from the dried root of Euphorbia fischeriana, on osteoclastogenesis induced by RANKL. The results showed that HJA significantly inhibited RANKL-induced osteoclast formation from primary bone marrow macrophages (BMMs). HJA also prevented bone resorption by mature osteoclasts in a dose-dependent manner. In addition, the expression of osteoclastic marker genes, such as tartrate-resistant acid phosphatase (TRAP), cathepsin K (Cts K) and MMP-9, was significantly inhibited by HJA. Furthermore, HJA also significantly inhibited RANKL-induced activation of NF-kappa B and phosphorylation of MAPK Our results indicate that HJA has an inhibitory role in the bone loss by preventing osteoclast formation as well as its bone resorptive activity. Therefore, HJA may be useful as a therapeutic reagent for bone loss-associated diseases. (C) 2015 Elsevier B.V. All rights reserved.

引用

页码：513 / 520

页数：8